Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts
Executive Summary
Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City
You may also be interested in...
Bristol Post-Accounting Focus Will Be On R&D Investment, Investor Relations
Maximizing Bristol-Myers Squibb's R&D return on investment will be one of the biggest challenges facing the company as it comes out of its accounting reforms, CFO Andrew Bonfield said
Bristol Post-Accounting Focus Will Be On R&D Investment, Investor Relations
Maximizing Bristol-Myers Squibb's R&D return on investment will be one of the biggest challenges facing the company as it comes out of its accounting reforms, CFO Andrew Bonfield said
Novartis E-Trial Program Will Help Reduce Clinical Trial Personnel By 25%
Novartis' productivity improvements through electronic data capture will result in an approximate one-quarter reduction in data management personnel and clinical research associates by January 2004